Milk Allergy Clinical Trial
Official title:
The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy
Verified date | March 2012 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine if small oral and sublingual doses of milk protein are safe and effective in decreasing sensitivity to cow's milk in allergic children.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | June 2015 |
Est. primary completion date | June 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Years to 21 Years |
Eligibility |
Inclusion Criteria: - Are age 6 to 21 years - Provide signed informed consent (by parent or legal guardian if the subject is a minor), and informed assent if applicable - Have a history of symptomatic reactivity to cow's milk (i.e. Eczema, urticaria, upper or lower respiratory symptoms, GI disturbances, other rash or oral symptoms) - Have a positive skin prick test (defined as wheal 3 mm = negative control) and cow's milk-IgE > 0.35 kIU/L - Have a positive OFC to cow's milk at a cumulative dose of less than 184 milligrams of cow's milk intact protein (2,400 mg total milk protein). - Are using appropriate birth control if subject is female and of child bearing age. - Have self-injectable epinephrine (ie. EpiPen® or EpiPen Jr.®) available at home Exclusion Criteria: - Have a history of severe anaphylaxis defined as hypoxia (cyanosis or SpO2 = 92% at any stage), hypotension, confusion, collapse, loss of consciousness; or incontinence - Have a history of intubation related to asthma - Tolerate more than 184 milligrams of intact cow's milk protein at initial OFC - Are pregnant or lactating - Have a viral URI or gastroenteritis within 7 days of OFC (OFC needs to be rescheduled) - Have pulmonary function tests <80% of predicted (FEV1) or clinical history consistent with more than moderate persistent asthma - Are currently taking greater than medium dose inhaled corticosteroid (>400 mcg/day fluticasone or fluticasone equivalent if = 12 years old or > 600 mcg/day if > 12 years old) - Are unable to discontinue antihistamines for 5 days for long acting and 3 days for short acting prior to skin testing or food challenges - Have used systemic corticosteroids within 4 weeks prior to baseline visit - Are receiving omalizumab, beta-blocker, ACE inhibitor or tricyclic antidepressant therapy - Have a chronic disease (other than asthma, atopic dermatitis or rhinitis) requiring therapy (e.g., heart disease, diabetes) - Have participated in any interventional study for treatment of a food allergy in the past 12 months - Have a severe reaction at initial DBPCFC, defined as either: Life-threatening anaphylaxis, or Reaction requiring hospitalization |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Hospital | Baltimore | Maryland |
United States | Duke University | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Robert A. Wood | Duke University, Greer Laboratories |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint is clinical response to treatment, defined as (1) tolerating ten times the initial oral food challenge threshold dose, OR (2) tolerating the maximum oral food challenge dose at the oral food challenge, at completion of immunotherapy. | Approximately 1 1/2 years. | No | |
Secondary | The proportion of patients who maintain a clinical response after withdrawal of treatment for one week. | Approximately 1 1/2 years. | No | |
Secondary | The proportion of patients who maintain a clinical response after withdrawal of treatment for six weeks. | Approximately 1 1/2 years. | No | |
Secondary | Incidence of all serious adverse events during the study | Approximately 1 1/2 years. | Yes | |
Secondary | Incidence of all adverse events during the study. | Approximately 1 1/2 years. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01950533 -
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
|
||
Completed |
NCT02579876 -
Milk Patch for Eosinophilic Esophagitis
|
Phase 2 | |
Completed |
NCT04318483 -
Characteristic and Evolution of an Atypical IgE-mediated Cow Milk Allergy Form With Hands and Feet Angio-oedema
|
||
Completed |
NCT02317952 -
Formula for Children With Cow's Milk Allergy
|
N/A | |
Completed |
NCT00968110 -
Xolair Treatment for Milk Allergic Children
|
Early Phase 1 | |
Recruiting |
NCT03309488 -
Basophil Activation Test to Diagnose Food Allergy
|
||
Completed |
NCT00328731 -
Milk ALLERGY ELIMINATION THROUGH NAET® (Nambudripad's Allergy Elimination Techniques).
|
Phase 1/Phase 2 | |
Recruiting |
NCT05309772 -
The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy
|
N/A | |
Terminated |
NCT02719405 -
Impact of Infant Formula on Resolution of Cow's Milk Allergy
|
Phase 2 | |
Completed |
NCT01361347 -
Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children
|
Phase 4 | |
Completed |
NCT01157117 -
OIT and Xolair® (Omalizumab) in Cow's Milk Allergy
|
Phase 2 | |
Recruiting |
NCT03819556 -
Swedish Study of Immunotherapy for Milk Allergy in Children
|
N/A |